Diana I. Brixner

Diana I. Brixner, RPh, PhD, FAMCP

Languages spoken: German, English

Academic Information

Departments Primary - Pharmacotherapy , Adjunct - Pediatrics

Divisions: Clinical Pharmacology

Currently, I am a Professor in the Department of Pharmacotherapy, Adjunct Professor in the Department of Population Health Sciences and Pediatrics in the Divisions of Health Systems Innovation Research and Clinical Pharmacology and Executive Director of the Pharmacotherapy Outcomes Research Center at the University of Utah. My research focus is on the design, conduct, and communication of pharmacoeconomic and outcomes research studies to demonstrate the value of pharmaceutical and related therapies from the perspective of the private and public payer. I am also a Research Associate at the Institute of Public Health, Medical Decision Making and Health Technology Assessment in the Department of Public Health and Health Technology Assessment at UMIT - University for Health Sciences, Medical Informatics and Technology in Hall i.T., Austria. This appointment supports my international collaborations in oncology research, personalized medicine and value assessment. During my career, I have published over 150 articles in peer-reviewed journals, authored three book chapters, have one issued patent, and have been an invited speaker at a variety of national and international professional meetings. I am a founding member, served on the Executive Board, as well as the Health Policy and Science Council and am a past president of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR). In addition, I am a long-standing member and past president of the Academy of Managed Care Pharmacy (AMCP), currently serve as a Director on the Board of the AMCP Biologics & Biosimilars Collective Intelligence Consortium (BBCIC), and have been named as a fellow of the Academy.

Education History

Undergraduate University of Rhode Island
 BS
Doctoral Training University of Utah
 PhD
Certification University of Health Sciences, Medical Informatics and Technology
 Certificate
Certification University of Health Sciences, Medical Informatics and Technology (UMIT)
 Certificate
Other Training University of Health Sciences, Medical Informatics and Technology
 Certificate

Selected Publications

Journal Article

  1. Ghate SR, Porucznik CA, Said Q, Hashibe M, Joy E, Brixner D (2013). Association Between Second-generation Antipsychotics and Changes in Body Mass Index in Adolescents. The Journal of adolescent health, 52(3), 336-43.
  2. Hawkes JE, Mittal M, Davis M, Brixner (2019). Impact of Online Prescription Management Systems on Biologic Treatment Initiation. Advances in therapy, 36(8), 2021-2033. (Read full article)
  3. Saverno K, Neu, G, Schmidt S, Wolf D, Conrads-Frank A, Jahn B, Sroczynski G, Brixner, D (2013). Medical Decision Analysis for the First-line Therapy of Chronic Myeloid Leukemia. Leukemia & lymphoma,
  4. Kuehl M, Brixner DI, Broom AD, Avery TL, Blakley R (1998). Cytotoxicity uptake, polyglutamate formation, and antileukemic effects of 8-deaza analogues of methotrexate and aminopterin in mice. Cancer research, 48((6)), 1481-8.
  5. Vermeulen LC, Windisch PA, Rydman RJ, Bruskiewitz RH, Brixner DI, Vlasses P (2000). Using a multihospital systems framework to evaluate and establish drug use policy. Journal of medical systems, 24(4), 235-46. (Read full article)
  6. Trost LF 3rd, Wender RC, Suter CC, Rosenberg JH, Brixner DI, Von Worley AM, Gunter MJ, National Epilepsy Management Panel (2005). Management of epilepsy in adults. Diagnosis guidelines. Postgraduate medicine, 118(6), 22-6. (Read full article)
  7. Dhamane AD, Martin BC, Brixner DI, Hudson TJ, Said (2013). Metabolic monitoring of patients prescribed second-generation antipsychotics. Journal of psychiatric practice, 19(5), 360-74. (Read full article)
  8. Brixner DI, Oderda GM, Nickman NA, Beveridge R, Jorgenson J (2006). Documentation of chemotherapy infusion preparation costs in academic- and community-based oncology practices. Journal of the National Comprehensive Cancer Network, 4(3), 197-208. (Read full article)
  9. Brixner DI, Oderda GM, Nickman NA, Servatius D, Lambert A, Bancroft F, Bretzel R, Beveridge R, Vermulen L, Lentz (2005). Documentation of pharmacy cost in the preparation of chemotherapy infusions in academic and community-based oncology practices. Journal of the National Comprehensive Cancer Network,
  10. Schwarzer R, Rochau U, Saverno K, Jahn B, Bornschein B, Muehlberger N, Flatscher-Thoeni M, Schnell-Inderst P, Sroczynski G, Lackner M, Schall I, Hebborn A, Pugner K, Fehervari A, Brixner DI, Siebert U Systematic overview of cost-effectiveness thresholds in ten countries across four continents with a special focus on personalized cancer medicine. Personalized medicine,
  11. Frost N, Freeman J, Brixner D, Mort J, Clem J, Ngorsuraches (2019). Patients' preferences and willingness-to-pay for disease-modifying therapies. Multiple sclerosis and related disorders, 35, 55-60. (Read full article)
  12. Brixner D, Rubin DT, Mease P, Mittal M, Liu H, Davis M, Ganguli A, Fendrick A (2019). Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending. Journal of managed care & specialty pharmacy, 25(7), 770-779. (Read full article)

Abstract

  1. Stanford J, Martin J, Gibson M, Birdsall E, Brixner D Use of Clomiphene Citrate in the University of Utah Community Clinics.